Northside Hospital has been selected as one of seven recipients of the "Improving the Precision Oncology Care Pathway" grant, a national initiative led by the Association of Cancer Care Centers (ACCC) in collaboration with Eli Lilly and Company.
Why it matters: The grant supports hospitals and physician groups in developing targeted solutions to address gaps in precision oncology care, ensuring more patients benefit from advanced molecular testing and personalized treatments.
Northside’s focus: Northside will use the funding for its Genomics Care Coordination Pilot, aimed at improving how genomic data is integrated into cancer treatment decisions. The hospital will focus on optimizing care coordination, reducing barriers to genomic testing and improving patient outcomes in precision oncology.
“We are honored to receive this grant,” said Drew Snyder, director of oncology quality and support services at Northside Hospital Cancer Institute. “The funds will provide increased support to our physicians and clinical teams and will expedite treatment decisions for patients.”
“The advancements of research in genomics and personalized oncology care are constantly changing and improving patient outcomes,” Snyder added. “Northside Hospital Cancer Institute will set the foundation for an integrated and expedient approach to precision oncology in a community cancer center setting.”
Other grant recipients include Parkview Hospital, Sanford Health, The Queen’s Medical Center, Thomas Jefferson University, the University of Alabama Birmingham, and the University of Washington. Each awardee will implement quality improvement initiatives to enhance precision oncology care.
Learn more about cancer research at Northside Hospital Cancer Institute.
